Erman Akkus on GLP1 Agonists in T2DM and Risk of Urological Cancers

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:

“GLP1 Agonists in T2DM and Risk of Prostate Kidney and Bladder Cancers

Bladder cancer
HR 147 106204 p 002
compared to SGLT2 inhibitors

Kidney cancer
HR 145 113186 p 0003
compared to metformin

Prostate cancer
HR 132 107163 p 0010
compared to insulin

Although the treatment of diabetes is crucial these data may effect treatment choice in individual cases.”